Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive data generated in exosome collaboration

11 Oct 2021 07:00

RNS Number : 5689O
ReNeuron Group plc
11 October 2021
 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Positive data generated in exosome programme collaboration

 

Significantly improved delivery of functional proteins to the brain demonstrated in vivo

Exosomes have potential to transform effective drug delivery for key neurological diseases

 

ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron's novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

 

In an ongoing collaboration with scientists at the University of Salamanca, Spain, ReNeuron has sought to determine whether its stem cell-derived exosomes can deliver a therapeutic protein to the corpus striatum; a region of the brain affected by disabling neurological diseases such as stroke, Parkinson's Disease and Huntington's disease.

 

Major pharmaceutical companies have identified therapeutic proteins that are effective in treating a variety of neurological diseases. However, there are major issues associated with the delivery of these protein therapeutics, which include the poor stability in living organisms, given that proteins rapidly break down and do not last long in the body; as well as issues surrounding poor tissue distribution due to an inability to target specific tissues. Whilst these issues cannot be overcome by simply administering more protein, as this can have unwanted side-effects, ReNeuron believes that its proprietary exosomes have the potential to address both these issues due to their natural tissue-targeting ability and superior stability characteristics.

 

Studies performed in collaboration with the University of Salamanca established that exosomes administered intrathecally were capable of delivering a therapeutic protein in an animal model (in vivo) to regions of the brain at a functional activity level much greater than that seen when simply supplying the protein alone. Contrary to this, studies performed in the laboratory showed no difference in delivery between the exosomal based protein and the protein alone. This difference between the efficiency of in vivo delivery versus in vitro delivery suggests that the exosome linked proteins were able to overcome the obstacle of protein breakdown and tissue targeting in the brain that was not possible with the native protein. The in vivo results are key in showing that ReNeuron's exosome delivery technology offer a striking higher stability, more targeted delivery, and an increase in potency, therefore potentially solving the delivery issues that can be experienced with therapeutic proteins.

 

Dr. Stefano Pluchino, Chief Scientific Officer of ReNeuron, commented: "I am delighted to see these extremely compelling data showing that exosomes efficiently deliver therapeutic proteins to targeted brain regions associated with severe neurological diseases. These data are the foundation of one of the main corporate programmes at ReNeuron and highlight the possibility to deliver other payloads using the same principles and technology platform, providing improved tissue distribution and specificity. This exciting strategy could potentially be used to deliver single therapies or multiple therapeutics with exosomes, enabling a number of exciting next generation precision medicine approaches."

 

Olav Hellebø, CEO, commented: "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain. In 2020 we refocussed the business on our exosome platform, as well as our retinal disease programme and iPSC platform, and these results show just how significant the potential is for exosomes to become a novel means of delivering third party biological drugs to the brain and other regions of the body. This is exciting news for the major pharmaceutical and biotechnology partners that we have collaboration agreements with and underpins the commercial opportunity that our platform provides."

 

 

ENDS

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

+44 (0)20 7710 7600

Ben Maddison, Stewart Wallace

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

Stefano Aquilino (Sales & Corporate Broking)

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLBDGDUGDGBI
Date   Source Headline
19th May 20091:21 pmRNSHolding(s) in Company
19th May 20091:18 pmRNSHolding(s) in Company
18th May 20091:06 pmRNSHolding(s) in Company
18th May 20097:00 amRNSFinal Closing of the Placing
14th May 20093:02 pmRNSThird Closing Of The Placing
14th May 200910:43 amRNSRegulatory update
1st May 20097:00 amRNSReN001 data to be presented at US conference
9th Apr 20097:00 amRNSSuccessful automation of stem cell manufacturing
8th Apr 20099:51 amRNSHolding(s) in Company
8th Apr 20099:43 amRNSHolding(s) in Company
7th Apr 20097:00 amRNSSecond Closing of the Placing
6th Apr 20097:00 amRNSPositive pre-clinical data with CTX stem cell line
3rd Apr 200911:19 amRNSResult of EGM and First Closing of the Placing
12th Mar 20097:00 amRNSAnnounces Fundraising and Conversion of Loan Notes
24th Feb 20094:03 pmRNSHolding(s) in Company
26th Jan 20097:00 amRNSReNeuron licenses stem cell line to BioFocus DPI
21st Jan 20097:00 amRNSReNeuron clarifies press comments
19th Jan 20094:00 pmRNSUpdate on ReNeuron's clinical trial
19th Jan 20097:00 amRNSReNeuron gains approval to commence trial
28th Nov 20087:00 amRNSInterim Results
24th Nov 20087:00 amRNSAppointment of NED
14th Nov 20083:30 pmRNSResearch Update
19th Sep 200810:46 amRNSResult of AGM
19th Sep 20087:00 amRNSAGM Statement
7th Aug 20083:33 pmRNSAnnual Report and Accounts
15th Jul 20087:00 amRNSResearch Update
24th Jun 20087:00 amRNSFinal Results
24th Jun 20087:00 amRNSRe: Fund Raising
23rd Jun 20083:38 pmRNSHolding(s) in Company
19th Jun 20084:33 pmRNSNotice of Results
11th Jun 20087:00 amRNSRe: ISSCR Conference
29th May 20087:00 amRNSRe: Contract
21st May 20087:00 amRNSNotice of US Patent Grant
20th May 200810:46 amRNSRe: UK Government Vote
23rd Apr 20087:00 amRNSResearch Update
19th Mar 20087:00 amRNSRegulatory Update
1st Feb 20087:01 amRNSResearch Update
7th Jan 20081:42 pmRNSDirector/PDMR Shareholding
3rd Jan 20081:28 pmRNSRegulatory Update
11th Dec 20077:00 amRNSTo Present at Conference
28th Nov 200711:25 amRNSTo Present at US Conference
28th Nov 200711:13 amRNSNotice of Results
21st Nov 200711:30 amRNSResearch Update
8th Nov 20077:30 amRNSContract with ReNeuron
18th Oct 20077:01 amRNSResearch Update
6th Sep 200711:12 amRNSAGM Result
6th Sep 20077:00 amRNSResearch Update
20th Aug 20077:02 amRNSRe: AIM Rule 26
10th Aug 200712:53 pmRNSHolding(s) in Company
8th Aug 20075:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.